Uniqure NV (QURE) Shares Sold by Spark Investment Management LLC

Spark Investment Management LLC lowered its stake in shares of Uniqure NV (NASDAQ:QURE) by 13.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 307,200 shares of the biotechnology company’s stock after selling 48,500 shares during the period. Spark Investment Management LLC’s holdings in Uniqure NV were worth $1,775,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new stake in Uniqure NV during the fourth quarter valued at approximately $7,089,000. City Financial Investment Co Ltd purchased a new stake in Uniqure NV during the fourth quarter valued at approximately $1,492,000. FMR LLC raised its stake in Uniqure NV by 4.1% in the fourth quarter. FMR LLC now owns 1,175,118 shares of the biotechnology company’s stock valued at $6,580,000 after buying an additional 46,200 shares during the last quarter. FT Options LLC raised its stake in Uniqure NV by 116.1% in the fourth quarter. FT Options LLC now owns 65,158 shares of the biotechnology company’s stock valued at $365,000 after buying an additional 35,000 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Uniqure NV during the fourth quarter valued at approximately $182,000. 29.84% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Uniqure NV (NASDAQ:QURE)

Uniqure NV (QURE) traded down 1.46% during mid-day trading on Monday, reaching $5.40. 31,528 shares of the company traded hands. The stock has a 50-day moving average of $5.30 and a 200 day moving average of $5.85. The stock’s market capitalization is $137.39 million. Uniqure NV has a 52-week low of $4.72 and a 52-week high of $14.59.

Uniqure NV (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.16. The firm had revenue of $3.32 million for the quarter, compared to analysts’ expectations of $4.20 million. Uniqure NV had a negative net margin of 370.57% and a negative return on equity of 70.75%. Equities research analysts expect that Uniqure NV will post ($3.41) earnings per share for the current year.

WARNING: “Uniqure NV (QURE) Shares Sold by Spark Investment Management LLC” was first posted by Mideast Time and is owned by of Mideast Time. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.mideasttime.com/uniqure-nv-qure-shares-sold-by-spark-investment-management-llc/1753118.html.

QURE has been the topic of several analyst reports. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Uniqure NV in a research report on Wednesday, March 22nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 price target on shares of Uniqure NV in a research report on Wednesday, April 12th. ValuEngine lowered shares of Uniqure NV from a “sell” rating to a “strong sell” rating in a research report on Friday. Zacks Investment Research lowered shares of Uniqure NV from a “buy” rating to a “sell” rating in a research report on Wednesday, May 17th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Uniqure NV in a research report on Wednesday, May 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $15.28.

Uniqure NV Company Profile

uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:QURE”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).

Receive News & Ratings for Uniqure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure NV and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.